Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Performing multiple biomarker tests delays initiation of amyloid-targeting treatments.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

Features predicting data exclusion in imaging studies of Alzheimer's disease.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

Illuminating proinflammatory myeloid cells with PET tracers targeting GPR84.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Invited commentary on: "Employment disruption and missed workdays after neoadjuvant therapy receipt for high-risk gastrointestinal cancer".

Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract·2026
Same author

Usage and positivity rates of Alzheimer's disease biomarkers in a memory clinic.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Factors influencing accelerated progression in behavioral variant frontotemporal dementia.

Journal of neurology·2026
Same journal

Evidence for progressive neurodegeneration in iatrogenic cerebral amyloid angiopathy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Human brain connectome profiles mediate the relationship between pathology burden and clinical phenotypes in Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Kat5 cKO mouse replicates biological domain signatures associated with Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Evaluation of CSF and plasma tau species as fluid surrogate candidates for tau PET in prodromal to moderate Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Associations of self-reported obstructive sleep apnea with cognition and dementia risk in cognitively unimpaired middle-aged adults.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Inflammation profiles in Alzheimer's disease relate to cognition and neurodegeneration.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
See all related articles

Related Experiment Video

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

Biomarkers.

Kavon J Sharifi1, Jessica Hu2, Hope Shimony1

  • 1Washington University School of Medicine, St. Louis, MO, USA.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 24, 2025
PubMed
Summary
This summary is machine-generated.

A portable, low-field MRI shows promise for monitoring Alzheimer's Disease patients on lecanemab therapy, accurately detecting ARIA-E (edema) but not ARIA-H (microhemorrhage). This could improve access to essential MRI scans for patients and healthcare facilities.

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Related Experiment Videos

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Area of Science:

  • Neurology
  • Medical Imaging
  • Pharmacology

Background:

  • Lecanemab, an FDA-approved Alzheimer's Disease (AD) immunotherapy, requires regular MRI monitoring for amyloid-related imaging abnormalities (ARIA).
  • ARIA can manifest as cerebral edema (ARIA-E) or microhemorrhage (ARIA-H), necessitating timely detection.
  • Current MRI requirements pose significant logistical and accessibility challenges for patients, caregivers, and healthcare facilities, potentially limiting treatment access.

Purpose of the Study:

  • To evaluate the viability of an ultra-low field, portable MRI system for baseline and safety monitoring of patients undergoing lecanemab therapy.
  • To compare the diagnostic performance of a portable low-field MRI against standard clinical MRI for detecting ARIA in Alzheimer's Disease patients.

Main Methods:

  • 31 patients with AD receiving or having discontinued lecanemab therapy were enrolled.
  • Participants underwent MRI scans using a 0.064T Hyperfine Swoop® Portable MR Imaging® system within one week of their clinical MRI.
  • Retrospective data analysis included patient age, ARIA history, and reads of both low-field and clinical MRI scans.

Main Results:

  • The low-field MRI system achieved 100% sensitivity in detecting mild and moderate ARIA-E.
  • The system was not sensitive to ARIA-H (microhemorrhages).
  • An incidental subdural hematoma detected on clinical MRI was also identifiable on the low-field MRI.

Conclusions:

  • Ultra-low field, portable MRI demonstrates high sensitivity for detecting ARIA-E, a key side effect of lecanemab.
  • This technology could serve as an adequate surrogate for standard 1.5/3T clinical MRI scans, potentially alleviating patient and healthcare system burdens.
  • Further validation is needed to confirm its role in routine monitoring for lecanemab-treated Alzheimer's patients, particularly for ARIA-H detection.